文献速递介入腹部DSACTMR

TRIPLET方案在TACE难治性中期肝细胞癌患者中的有效性与安全性

Effectiveness and Safety of TRIPLET Protocol in Patients with Intermediate-Stage Hepatocellular Carcinoma to Transcatheter Arterial Chemoembolization Refractory.
PubMed 文献 · Acad Radiol · 2025-06-06

回顾性多机构研究纳入275例TACE难治性中期HCC患者,比较HAIC联合阿帕替尼及卡瑞利珠单抗(TRIPLET方案)与单纯HAIC。倾向性评分匹配后,TRIPLET组中位OS 11.5个月 vs HAIC组7.8个月,中位PPS 8.6个月 vs 4.8个月,差异均有统计学意义。

要点

  • TACE难治性中期HCC中,TRIPLET方案中位OS 11.5个月,优于单纯HAIC的7.8个月。
  • TRIPLET方案中位PPS 8.6个月,优于单纯HAIC的4.8个月
  • 多因素分析显示HAIC治疗与较差OS相关(HR 1.92),AFP亦影响OS

核心结论

  • TRIPLET方案在TACE难治性HCC患者管理中显示出显著的安全性和有效性。

研究设计与样本

  • 回顾性多机构研究,2019年4月至2024年9月纳入275例经两名放射科医师依据mRECIST标准判定的TACE难治性中期HCC患者,分为HAIC组(n=117)和TRIPLET组(n=158),采用倾向性评分匹配减少选择偏倚。

诊断标准与关键数值

  • TACE难治性判定依据mRECIST标准,由两名放射科医师评估;PSM 1:1后TRIPLET组中位OS 11.5个月 vs HAIC组7.8个月(P < 0.001),中位PPS 8.6个月 vs 4.8个月(P < 0.001)。

临床应用与阅片要点

  • 多因素分析显示影响OS的因素为甲胎蛋白(HR 2.14;95%CI 1.26-3.98;P=0.006)和HAIC治疗(HR 1.92;95%CI 1.16-3.33;P=0.012)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

RATIONALE AND OBJECTIVE: The treatment scheme in hepatocellular carcinoma (HCC) refractory to transarterial chemoembolization (TACE) is still controversial.

OBJECTIVE: To compare the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) combined with apatinib plus camrelizumab (TRIPLET protocol) versus HAIC alone for HCC refractory to TACE.

MATERIALS AND METHODS: From April 2019 to September 2024, a total of 275 patients with intermediate-stage HCC refractory to TACE based on modified Response Evaluation Criteria in Solid Tumors criteria by two radiologists were reviewed, classifying into the HAIC group (n = 117) and TRIPLET group (n = 158). Propensity score matching (PSM) method was used to reduce the selective bias. The overall survival (OS) and post progression-free survival (PPS) were compared using the Kaplan-Meier method with log-rank test. Multivariable analyses of independent prognostic factors were evaluated by means of the forward stepwise Cox regression model.

RESULTS: After PSM 1:1, the median OS was 11.5 months in TRIPLET group was longer significantly than that (median OS was 7.8 months) in HAIC group (P < 0.001). The median PPS was 8.6 months in TRIPLET group was longer significantly than that (4.8 months) in the HAIC group (P < 0.001). Multivariate analyses showed that the factors that significantly affected the OS were α-fetoprotein (hazard ratio [HR]: 2.14; 95% confidence interval [CI]:1.26-3.98; P = 0.006), and HAIC treatment (HR: 1.92; 95% CI: 1.16-3.33; P = 0.012). Multivariate analyses showed that the factors that significantly affected the PPS were albumin-bilirubin grade 2 (HR:1.63; 95% CI: 1.03-2.60; P = 0.037), tumor diameter > 5 cm (HR: 1.67; 95% CI: 1.34-2.09; P < 0.001) and HAIC treatment (HR: 1.67; 95% CI: 1.08-2.63; P = 0.025) significantly affected the PPS.

CONCLUSION: This TRIPLET protocol has significant safety and effectiveness in the management of patients with HCC refractory to TACE.

DESIGN: A retrospective, multi-institutional study.

来源:Acad Radiol,查看原文。版权归原作者所有。

引用

  1. Zhao Y, Wu Y, Lin K, et al. Effectiveness and Safety of TRIPLET Protocol in Patients with Intermediate-Stage Hepatocellular Carcinoma to Transcatheter Arterial Chemoembolization Refractory. Acad Radiol. 2025. PMID: 40480939. doi:10.1016/j.acra.2025.05.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。